• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by RadNet Inc.

    4/20/26 5:16:03 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    DEFA14A 1 radnet_defa14a.htm FORM DEFA 14A

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934

     

    Filed by the Registrant ý

     

    Filed by a party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨ Definitive Proxy Statement

    ý Definitive Additional Materials

    ¨ Soliciting Material Pursuant to §240.14a-12

     

    RADNET, INC.

    (Name of Registrant as Specified In Its Charter)

     

    __________________________________________

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.

     

    ¨ Fee paid previously with preliminary materials.

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

       

     

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V94682 - P49188 RADNET, INC. 1510 COTNER AVENUE LOS ANGELES, CA 90025 RADNET, INC. 2026 Annual Meeting Vote by June 1, 2026, 11:59 PM ET. For shares held in an employee share plan, vote by May 28, 2026, 11:59 PM ET. Vote in Person at the Meeting* June 2, 2026 10:00 AM, PT 1510 Cotner Avenue Los Angeles, CA 90025 You invested in RADNET, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 2, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10 - K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 19, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

       

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V94683 - P49188 For 1. Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified. Nominees: 1) Howard G. Berger, M.D. 04) Lawrence L. Levitt 2) A. Gregory Sorensen, M.D. 05) Gregory E. Spurlock 3) Laura P. Jacobs 06) David L. Swartz For 2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. For 3. An advisory vote to approve the compensation of the Company’s Named Executive Officers. For 4. The approval of an amendment and restatement to the Company’s Equity Incentive Plan. NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof. Voting Items Board Recommends

       

     

     

     

     

     

     

     

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    SEC Filings

    View All

    SEC Form DEFA14A filed by RadNet Inc.

    DEFA14A - RadNet, Inc. (0000790526) (Filer)

    4/20/26 5:16:03 PM ET
    $RDNT
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by RadNet Inc.

    DEF 14A - RadNet, Inc. (0000790526) (Filer)

    4/20/26 5:15:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RadNet Inc.

    SCHEDULE 13G/A - RadNet, Inc. (0000790526) (Subject)

    3/27/26 11:35:46 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions

    The expanded collaboration builds on the companies' existing joint initiative by bringing to market enhanced capabilities of DeepHealth's new AI-powered Breast Suite, including ProFound Pro and Safeguard Review GE HealthCare to feature latest technologies to help ensure optimized breast care outcomes across mammography and ultrasound at SBI's 2026 Breast Cancer Imaging Symposium GE HealthCare (NASDAQ:GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The an

    4/16/26 4:05:00 PM ET
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities

    RadNet, Inc. to Present Today at the KeyBanc Capital Markets Healthcare Forum

    LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). There will be simultaneous and archived webcasts available at https://wsw.com/webcast/key40/rdnt/1686072 About RadNet, Inc.RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of

    3/17/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. to Present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12th

    LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12, 2026 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). There will be simultaneous and archived webcasts available at https://urldefense.com/v3/__https://cc.webcasts.com/barc002/031026a_js/?entity=144_X3VLDEI__;!!COmMWt7_Sw!XlHi2Z0Y8oljWTGFQhCAlqx-WUpj99UPNp1_sposW-TqahO41Keizcqhw9B4eULlXCe9bGpTDgrQlnQ9cI0$ Det

    3/11/26 4:15:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sorensen Alma Gregory

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/23/26 4:15:05 PM ET
    $RDNT
    Medical Specialities
    Health Care

    SEC Form 4 filed by Sorensen Alma Gregory

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/18/26 7:38:51 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Chief Strategy Officer Sorensen Alma Gregory converted options into 62,964 shares, increasing direct ownership by 5% to 1,244,842 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/12/26 5:52:02 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care